Safety and Immunogenicity of a Prototype Oral Whole-Cell Killed CampylobacterVaccine Administered with a Mucosal Adjuvant in Non-Human Primates

摘要

Campylobacter jejuni is now recognized as a major public health problem in boththe developed and developing world, where an estimated 400 million cases of Campylobacter gastroenteritis occur annually'. C. jejiuni is also considered to be the second most common bacterial cause of travellers' diarrhea, with estimated